Tough on Duchenne.
So it's easier to be him.

Why AGAMREE®?

Different mechanism of action: Developed to uncouple anti-inflammatory effects and certain corticosteroid-mediated adverse effects1,2

Proven efficacy: Improved muscle strength and motor function3

Well tolerated: Established safety and tolerability profile in clinical studies3

Approved in children as young as 2 years of age: Orange-flavored oral suspension indicated for boys with Duchenne muscular dystrophy(DMD) aged 2 years and older3

AGAMREE Is a Corticosteroid With a Novel Structure

AGAMREE has a novel structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in DMD1,3

In vitro data have shown that structural differences impact the way AGAMREE interacts with the glucocorticoid receptor and the mineralocorticoid receptor1*

  • AGAMREE was developed to uncouple anti-inflammatory effects and certain corticosteroid-mediated adverse effects1,2

Like corticosteroids commonly prescribed for DMD2,4

  • Inhibits NF-кB activity

Developed to retain potent anti-inflammatory action

Developed to retain potent anti-inflammatory action

Unlike corticosteroids commonly prescribed for DMD1,2,4

In vitro data have shown:

  • Reduced GR-dependent activation of gene expression
  • Antagonistic effect on mineralocorticoid receptor

Developed to reduce
GRE-mediated adverse effects

Developed to reduce GRE-mediated adverse effects

AGAMREE acts through the glucocorticoid receptor to exert its anti-inflammatory effects. The precise mechanism by which AGAMREE exerts its effect in patients with DMD is unknown.3
GR, glucocorticoid receptor; GRE, glucocorticoid response element; NF-кB, nuclear factor kappa B.

Proven Efficacy
and Safety

View clinical trial results for the efficacy and safety of AGAMREE in boys with DMD

View Data

Get Your Patients
Started on AGAMREE

Enroll your patients in Catalyst Pathways® for access to a wide range of personalized support and programs

Enroll Now